PANEL | Attracting Big Pharma back to Australia with Australian ‘Golden Goose’ Biotech’s: Sourcing innovating opportunities

31 Jul 2023Healthcare
Purchase access to view full content
PANEL | Attracting Big Pharma back to Australia with Australian ‘Golden Goose’ Biotech’s: Sourcing innovating opportunities

PANEL | Attracting Big Pharma back to Australia with Australian ‘Golden Goose’ Biotech’s: Sourcing innovating opportunities

31 Jul 2023Healthcare
About the speakers
  • Dr Anand Gautam
    Dr Anand Gautam
    Executive Director & Emerging Science Lead, Emerging Science & Innovation, Asia & APAC (Australia & New Zealand), at Pfizer Worldwide R&D
    Dr Anand Gautam has had wide-ranging leadership roles in R&D and innovation strategies in Inflammation/Autoimmune Diseases/Cancer at international biotech and pharmaceutical companies for over 30 years. Anand has spent over 12 years as an academic in Immunology in prestigious research centres in the UK (PhD at University of London), US (post-doc at Stanford University, California), and Australia (Academic positions at ANU, Canberra & UQ, Brisbane). Before joining Pfizer as a Head of External Science & Innovation, ANZ & Southeast Asia in April 2017, Anand was a Senior Director of R&D Innovation Sourcing at Novo Nordisk, Copenhagen for eight years. Prior to that, Anand was VP of R&D at Progen (Brisbane, Australia), and SVP of External Science & Collaboration at Pharmexa (Denmark). Dr Gautam has obtained numerous grants to carry out his scientific research, including an NIH gran; a Career Development Award from Juvenile Diabetes Foundation International, USA; and a Howard Florey Young Investigator’s Award from the ANU, Canberra. Anand serves on number committees (e.g. AusBiotech and Bridge Program at MTPconnect, Australia), is a Life Science Queensland Ambassador, and is an Adjunct Professor at The Institute for Molecular Biosciences, University of Queensland
  • Dr Phil Kearney
    Dr Phil Kearney
    CEO at Axelia Oncology
    From 2007-2022 Phil was Head of External Licensing for Merck Sharp & Dohme. In that role he liaised with regional biotechnology companies and research institutes scouting for new chemical and biological entities with therapeutic potential, validated drug targets and new platform technologies in the Asia Pacific region (including India, South East Asia, Australia, & New Zealand). During his time at Merck, the significant deals in which Dr Kearney played totalled almost $2 billion. These included publicly disclosed deals with Vaxxas, Bionomics and Viralytics. His previous appointments include head of the academic Haematology Research Laboratory, St Vincents Hospital Sydney for over 12 years, focussing on ribozyme and gene therapy approaches to therapy in Chronic Myeloid Leukaemia. He then spent 7 years in European biotech including head of preclinical oncology studies at ActiveBiotech AB in Sweden, and at Santaris Pharma as Head of Biology, focussed on antisense mediated knock-down of RNA and miRNA targets in a number of indications. He holds an MBA from the University of Sydney and completed his PhD genetics at Monash University. He completed a post-doc at Imperial College London mapping the human Y chromosome and later worked on mapping the X chromosome at the Murdoch Institute in Melbourne
  • Dr Marthe D’Ombrain
    Dr Marthe D’Ombrain
    Senior Director & Head, Global Research Innovation at CSL
    Marthe has worked in the life sciences sector for over 20 years and has extensive leadership experience across industry and academia, both locally and internationally. Joining CSL in 2013, Marthe currently serves as the Senior Director & Head of Global Research Innovation and plays a key role in building and diversifying CSL’s global R&D portfolio. At CSL, Marthe has championed the establishment of an early stage fund – the CSL Research Acceleration Initiative – that establishes partnerships between CSL and global research organisations and invests in promising discoveries to accelerate translation and fast-track the development of innovative biotherapies to address unmet patient needs. Recently, Marthe has played a key role in the establishment of the new biomedical incubator that will be located at CSL’s new global corporate headquarters in the world-leading Melbourne Biomedical Precinct. Marthe is passionate about research collaboration and its potential for bringing new treatments to patients living with unmet medical needs.
  • Kathy Connell
    Kathy Connell
    Director at The Biotech Bridge
    Kathy Connell is the Founding Director of The Biotech Bridge, a private lifesciences consulting and advisory firm dedicated to realizing the goals and commercialisation ambitions of lifescience start-ups, entrepreneurs, innovators, academics and investors across pharmaceutical, medical device and consumer areas. For over 20 years Kathy has worked for biotech and multinational companies including Johnson and Johnson and Sanofi Aventis where she has been responsible for their external partnerships and growth strategy across pharmaceuticals, medical device and consumer health sectors. While at Johnson & Johnson Kathy was personally responsible for sourcing over 100 deals, worth in excess of $US1B as well as delivering countless search, evaluation, training and networking programs to support the development of this vibrant ecosystem. A recognised supporter of women in STEM, Kathy was awarded the Bio Melbourne Network Women in Leadership Award in 2018. Kathy co-founded and was on the Steering Committee of Medicines Australia’s Special Interest Group PAIG (Pharmaceuticals Australia Inclusion Group) dedicated to ensuring that Australia’s pharmaceutical industries develop and deliver policies promoting diverse, inclusive and equitable workplaces. Kathy is a registered psychologist and holds Post Graduate Diplomas in Health and Medical Law from the University of Melbourne, Educational Psychology from Monash University and bachelor’s degrees in applied science (Speech Pathology, LaTrobe University) and Psychology (Swinburne University). Based in Sydney, Kathy is currently completing the Australian Institute of Company Directors course.
  • Tam Nguyen
    Tam Nguyen
    Deputy Director Research at St Vincent’s Hospital Melbourne
    Associate Professor Tam Nguyen has over 20 years of working in the healthcare, health & medical research environment including tertiary teaching hospitals and research institute across Australia. Tam is the Deputy Director of Research at St Vincent’s Hospital Melbourne, one of the largest tertiary teaching and research hospitals in Melbourne. He holds academic appointments with the Melbourne Medical School and Monash Medical and sit on the Investment Committee of Horizon3Biote Fund. Tam also invest and advise early stage biotech and medtech companies across Australia and Singapore.

Key takeaways